ALLMedicine™ Nontuberculous Mycobacterial Lung Disease Center

Mar 3rd, 2023 - Background: Nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms that have been increasingly associated with human disease, commonly involving the lung. Post menopausal Caucasian women seem particularly predisposed to the devel...

Jan 20th, 2023 - Nontuberculous mycobacterial lung disease (NTM-LD) and Mycobacterium tuberculosis lung disease (MTB-LD) have similar clinical characteristics. Therefore, NTM-LD is sometimes incorrectly diagnosed with MTB-LD and treated incorrectly. To solve these...

Jan 19th, 2023 - The incidence of nontuberculous mycobacterial lung disease (NTM-LD) is increasing worldwide and in Eastern Asia. NTM-LD leads significant morbidity and mortality, around 25% within 5 years, but the treatment rate is low because the course of NTM-L...

Nov 5th, 2022 - The incidence of nontuberculous mycobacterial lung disease (NTM-LD) peaks in middle- and old age groups, coinciding with senescence; thus, chronic infectious diseases can accelerate frailty and worsen mental health in the elderly. In this study, w...

Aug 16th, 2022 - In women, slender body habitus has been reported to be one of the predisposing factors underlying the development and poor prognosis of non-tuberculous mycobacterial lung disease (NTM-LD). Given the lack of nutritional data contributing to treatme...

Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grad...

Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grad...

Mar 3rd, 2023 - Background: Nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms that have been increasingly associated with human disease, commonly involving the lung. Post menopausal Caucasian women seem particularly predisposed to the devel...

Jan 19th, 2023 - The incidence of nontuberculous mycobacterial lung disease (NTM-LD) is increasing worldwide and in Eastern Asia. NTM-LD leads significant morbidity and mortality, around 25% within 5 years, but the treatment rate is low because the course of NTM-L...

Aug 10th, 2022 - Currently, the annual prevalence of nontuberculous mycobacterial lung disease is increasing year by year. the clinical presentation of NTM is similar to that of tuberculosis, but most NTM is severely resistant to antibiotics, making it difficult t...

Mar 31st, 2022 - A single center, randomized, phase II, single blinded, two-dose level trial aimed at testing anti-mycobacterial activity of CYT107 in patients with non-tuberculous mycobacteria lung disease (NTMLD). A total of 12 evaluable NTMLD patients from Wash...

Nov 25th, 2020 - The incidence of pulmonary disease caused by nontuberculous mycobacteria (NTM) has been increasing, and a substantial proportion of these patients have no preexisting lung disease and no demonstrable immunodeficiency. These patients are predominan...

Apr 12th, 2022 - Living in coastal areas of Florida and California has great appeal for many, with the warm, sunny climate and nearby freshwater and saltwater. But, unknown to many, those balmy coasts also carry the risk of infection from nontuberculous (atypical)...

Jan 21st, 2020 - A new study of claims-based data has found that the incidence and prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in most states. Dr.

Jan 21st, 2020 - A new study of claims-based data has found that the incidence and prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in most states. Dr.

Oct 1st, 2018 - The US Food and Drug Administration (FDA) has approved amikacin liposome inhalation suspension (Arikayce, Insmed) for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. Arika...

Oct 1st, 2018 - The US Food and Drug Administration (FDA) has approved amikacin liposome inhalation suspension (Arikayce, Insmed) for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. Arika...